Tech capabilities to offer CMOs advantages in stable oral dosage sector, report

By Dan Stanton

- Last updated on GMT

photo - Denja1/iStock
photo - Denja1/iStock

Related tags Pharmacology

Niche technologies will differentiate CMOs looking for a slice of the steady oral dosage manufacturing industry, according to an industry report from ISR.

For contract manufacturing organisations (CMOs) dealing in oral dosage drugs, the next five years is likely to be steady, according to a report entitled ‘Oral Dosage Forms Market Trends and Outsourcing Dynamics,’ published by ISR.

The report is based on the responses of 105 pharma and biotech executives and, according to ISR Market Research Director Kate Hammeke, the survey found the outsourcing penetration of oral dosage forms is “anticipated to remain fairly steady over the next five years, with an upward shift of four percentage points.”

Furthermore, she told, the same is true for clinical trial manufacturing and outsourced dosage form development which will remain stable, growing at 1% and 2% respectively.

In such an environment, “CMOs will be able to gain an advantage over competitors through their technical capabilities and through the oral dosage forms offered by the CMO,”​ she added.

This corresponds with recent investments from a number of players looking to distinguish themselves through niche technology offerings.

Fareva​, for example, recently followed moves by Catalent​ into micronisation services. Patheon​ and AMRI​, meanwhile, have been focusing their M&A efforts on hard-to-make and controlled APIs. And firms including Pharmatek​ and Capsugel​ have invested in spray-dried dispersion technologies.

And regionally speaking, while India and China have been areas of growth for CMOs looking to take advantage of drugmakers offshoring oral dosage form manufacturing, Hammeke told us Eastern Europe is set to grow.

“Among respondents who offshore oral dosage manufacturing, Eastern Europe was identified as the region with the largest percentage of people who had not previously outsourced manufacturing to the region but plan to,”​ she said.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more